Portal de investigación
Factors associated with the number of drugs in darunavir/cobicistat regimens.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Martinez E
- Negredo E
- Knobel H
- Ocampo A
- Sanz J
- Garcia-Fraile L
- Martin-Carbonero L
- Lozano F
- Gonzalez-Domenech CM
- Gutierrez M
- Boix V
- Payeras A
- Torralba M
- Gonzalez-Cordon A
- Moreno A
- Alejos B
- Perez-Elias MJ
Grupos
Abstract
Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy.
Datos de la publicación
- ISSN/ISSNe:
- 0305-7453, 1460-2091
- Tipo:
- Article
- Páginas:
- 208-214
- DOI:
- 10.1093/jac/dkz399
- PubMed:
- 31586414
- Factor de Impacto:
- 2,124 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY OXFORD UNIV PRESS
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- RITONAVIR PLUS LAMIVUDINE; PROTEASE INHIBITOR MONOTHERAPY; OPEN-LABEL; VIRAL SUPPRESSION; TRIPLE TREATMENT; DUAL TREATMENT; THERAPY; MAINTENANCE; EFFICACY; DARUNAVIR/RITONAVIR
Cita
Martinez E,Negredo E,Knobel H,Ocampo A,Sanz J,Garcia L,Martin L,Lozano F,Gonzalez CM,Gutierrez M,MONTERO M,Boix V,Payeras A,Torralba M,Gonzalez A,Moreno A,Alejos B,Perez MJ. Factors associated with the number of drugs in darunavir/cobicistat regimens. J. Antimicrob. Chemother. 2020. 75. (1):p. 208-214. IF:5,790. (1).